Yi-Long Wu
0000-0002-3611-0258
Guangdong General Hospital and Guangdong Academy of Medical Sciences
53 papers found
Refreshing results…
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Meta-Analysis of First-Line Pemetrexed plus Platinum Treatment in Comparison with Other Platinum Based Doublet Regimens in Elderly East Asian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer
Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing
Clinical reaserch development of resistance mechanisms of EGFR-TKIs targeted therapy in patients with non-small cell lung cancer
Development of second-generation EGFR TKIs in lung cancer treatment
Advance in clinical research of non-small cell lung cancer vaccines
A paradigm shift in non-small-cell lung carcinoma treatment
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients].
Establishment and its biological characteristics of patient-derived lung cancer xenograft models
[A diagnostic model of cerebrospinal protein fingerprint pattern for brain metastases of non-small cell lung cancer].
Clinical implication of high level expression of Rad51 in non-small cell lung cancer
Missing publications? Search for publications with a matching author name.